Insight

Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24

Arndt Vogel/X

Jun 28, 2024, 13:48

Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24

Arndt Vogel shared on X:

“Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24.

NEST clinical trial, 20 MSS, 3 MSI,
pMSS: 50% cPCR rate,
Really active in MSI and MSS CRC.”

Source: Arndt Vogel/X

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.

Agenus Arndt Vogel Balstilimab BOT/BAL BOT/BAL immunotherapy botensilimab cancer colorectal cancer Dhan Chand ESMO ESMOGI24 European Society for Medical Oncology Garo Armen Hannover Medical School Jennifer Buell Mehraneh Jafari Metastatic colorectal cancer MSS CRC NEST trial OncoDaily Oncology Pashtoon Kasi Steven O'Day

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage